Shows
Surfing the MASH TsunamiS6 - E3.3 - Expert: GLI's Jeff McIntyre discusses implications of FDA job cuts on MASH drugsThis week's Expert is Jeff McIntyre, Vice President, Liver Programs at the Global Liver Institute. His major topic is how recent high-level FDA job cuts might affect MASH drug and diagnostics development. He also shares reactions to FibroSIGHT, HistoIndex's new digital pathology service for clinical practice. Highlight: Recent job cuts at the FDA will produce chaos in government and slow response to any emerging crises.Second Highlight: Patient self-advocacy becomes even more important in this environment.The conversation takes place on April 1, which lends context to Jeff's opening comment about the rate and n...2025-04-0631 minSurfing the MASH TsunamiS6 E3.2 - Newsmakers: FibroSIGHT™ Brings Clinical Trial Analytics to the ClinicThis week's newsmaker, Yukti Choudhury, Director of Clinical Development at HistoIndex, joins Roger Green to discuss FibroSIGHT, a new HistoIndex service that allows clinicians to use HistoIndex's Second Harmonic Generation (SHG) technology and analytics to determine specific CRN fibrosis level for patients with inconclusive NIT results. One reason FibroSIGHT is worthy of attention: This is the first time an in-depth analysis of clinical trial biopsy results is being placed at the service of clinical treatment. Another reason: Yukti states that demand for this technique could equal 163,000 cases this year, rising to one million by 2028. T...2025-04-0528 minSurfing the MASH TsunamiS6 - E3 - Drugs and Diagnostics Evolve as the FDA Devolves00:00:00 - Surf's Up: Season 6 Episode 3Surfing the MASH Tsunami continues its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on what studies on bariatric surgery and drugs in development can tell us about future treatment and explore some clinical trial questions. Our newsmaker, HistoIndex Director of Clinical Development Yukti Choudhury, introduces us to FibroSIGHT, which provides clinicians with highly precise biopsy analysis. Finally, our expert, Global Liver Institute Vice President, Liver Programs Jeff McIntyre, discusses the implications of recent US government job cuts on future MASH treatment options...2025-04-041h 12Surfing the MASH TsunamiS5 - E12.2 - MASH Drug Development: Improving Efficacy EndpointsIn this conversation, the panel discusses challenges in MASH Drug Development that are centered around efficacy endpoints and NAS scoring.This conversation starts with Will Alazawi suggesting that the MASH clinical trial field suffers from the previous experience with Hepatitis C, where medications became capable of eradicating disease in a fairly linear fashion. He suggests that MASH trials undervalue the value of simply preventing progression, which leads Sven Francque to note that preventing progression to cirrhosis is now accepted by regulators as an endpoint. Roger Green refers to last week's episode (S5 – E11), in which Mic...2024-04-2712 minSurfing the MASH TsunamiS4 E50.9 - Wrapping Up 2023 - An Interview With Novo Nordisk International Medical VP Michelle LongSurfing the MASH Tsunami continues its 2023 wrap-up conversations with Novo Nordisk International Medical Vice President Michelle Long, along with co-hosts Louise Campbell and Roger Green. The conversation focuses on advances in research, collaboration and insight creation the entire MASLD research community has made in 2023 and what this new perspective portends for the future of MASLD research.Michelle starts by using the word "momentum" to characterize the MASLD research community in 2023. She says the pace of change makes it impossible to summarize or describe the year easily, For example, the adoption of new nomenclature came six months ago...2024-01-1626 minSurfing the MASH TsunamiS4 E50.4 - Wrapping Up 2023 - An Interview With Dean TaiSurfing the MASH Tsunami continues its 2023 wrap-up conversations with HistoIndex Chief Scientific Officer Dean Tai, along with co-hosts Jörn Schattenberg and Roger Green. The conversation focuses on growth in the use of AI in Steatotic Liver Disease and some of the insights the profession is developing as a result. The conversation starts with Dean Tai and Jörn Schattenberg discussing the many promising advances in artificial intelligence over the past year. The two leaders agree both that the advances are providing exceptional new insights already, and will provide even greater insight when we can link AI to...2023-12-2735 minSurfing the MASH TsunamiS4-E49.3 - TLM2023 Wrap-Up - Panel Discusses NITs, AI And Bariatric SurgeryThis conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers what the panelists found exciting, important or striking about the presentations covering NITs, artificial intelligence and bariatric surgery at TLM2023. The conversation starts with Roger discussing a presentation in which Stephen Harrison shared HistoIndex data from the MAESTRO-NASH trial for resmetirom. HistoIndex’s proprietary methods produced results suggesting 34% improvement in the placebo group vs. 54% in the treatment group. More interesting, Dean Tai from HistoIndex suggested to Roger in a private conversation that this 1/3 placebo success rate holds fairly common across trials using these methods. Giv...2023-12-0314 minSurfing the MASH TsunamiS4-E49 - Wrapping Up TLM 2023 - A Panel Discussion With Scott Friedman And Laurent CasteraHepatology researchers and key opinion leaders Profs. Laurent Castera and Scott Friedman join Louise Campbell and Roger Green in the final element of our review coverage of TLM 2023. This far-ranging conversation moves beyond MASLD/NAFLD and MASH/NASH to consider an array of topics.The episode starts with Roger asking the other guests for their general impressions of the meeting. Three key insights: 1. "Pre-pandemic" levels of interaction and discussion among attendees2. Online meeting app was a "fail", becoming a topic of conversation in its own right while fostering confusion3. In the "frenzy"...2023-12-011h 00Surfing the MASH TsunamiS4-E27.6 - Deep Dive into AI and Pathology with Arun Sanyal and David KleinerSurfing NASH serves yet another preview of a highly anticipated and upcoming EASL Congress in Vienna, this time focusing on a strong lineup of abstracts and engaging sessions. This final conversation comes in the form of a topical extra-sode which fits seamlessly into our ongoing event coverage. Surfing NASH has partnered with HistoIndex to produce a deep dive session into AI and pathology with Arun Sanyal and David Kleiner. This high-caliber, stimulating discussion will improve your nuanced understanding of the challenges in using ordinal manual histopathology in NASH clinical trials and how AI systems might...2023-06-1834 minSurfing the MASH TsunamiS4-E27.5 - EASL Congress 2023: Exploring Technology for Identifying PatientsSurfing NASH extends its preview coverage of the upcoming EASL Congress with a three-part episode. This final conversation with Louise Campbell observes a paper she finds relevant to the recent NICE publishing of guidance around use of FibroScan in the primary care setting as well as International #NASHDay 2023. The presentation in reference is titled Patients with persistently abnormal liver biochemistry are under-investigated and can be rapidly identified using a novel case-finding database. Particularly, Louise notes that the paper is coming from the team of former podcast guest, Tim Jobson of Predictive Health Intelligence. The importance of being able to...2023-06-1811 minSurfing the MASH TsunamiS4-E27.4 - Previewing EASL Congress 2023 with Louise Campbell: Frontline ScreeningSurfing NASH extends its preview coverage of the upcoming EASL Congress with a three-part episode. This conversation continues on the theme of sessions and presentations of interest as anticipated by Louise Campbell alongside Roger Green. Louise begins by noting a poster on the causes of death in patients with NAFLD who presented on a spectrum of fibrosis stages at diagnosis. She goes on to note some fascinating conclusions of the study to tease links between liver disease and cardiovascular and extrahepatic cancer outcomes. Ultimately, Louise suggests that the evidence emerging strengthens her views on the need for stratifying NAFLD...2023-06-1815 minSurfing the MASH TsunamiS4-E27.3 - Abstract session - NAFLD: Clinical AspectsSurfing NASH extends its preview coverage of the upcoming EASL Congress with a three-part episode. This conversation comes from our final segment with Ian Rowe, Jörn Schattenberg and Roger Green. Jörn leads with thoughts around the Abstract session - NAFLD: Clinical Aspects. The session will touch on aspects that are, as Jörn puts it, “very close to what we're thinking today when we see patients.” He notes that topics covered around tools available now for treating and management will be of interest and utility for those seeing NASH patients. The group goes on to unpack this session...2023-06-1710 minSurfing the MASH TsunamiS4-E27.2 - Abstract session - NAFLD: TherapySurfing NASH extends its preview coverage of the upcoming EASL Congress with a three-part episode. This conversation continues to unpack the 2023 program with Ian Rowe, Jörn Schattenberg and Roger Green. Jörn begins by pointing to the Abstract session - NAFLD: Therapy which commences at 8:30 CEST on Friday morning. Specifically, he goes on to more closely detail a presentation related to time-restrictive eating which spurs an anecdote from Roger. Following, Ian describes what he finds fascinating about the opening presentation of this session concerning a Phase 2a, randomized, active-comparator-controlled, open-label study to evaluate the efficacy and safety of ef...2023-06-1712 minSurfing the MASH TsunamiS4-E27.1 - Unpacking the Program with Ian Rowe and Jörn SchattenbergSurfing NASH extends its preview coverage of the upcoming EASL Congress with a three-part episode. First up, Ian Rowe and Jörn Schattenberg speak to Roger Green about anticipations around the 2023 program and which abstracts are eye-catching and why. This conversation comes from that session and begins with Ian’s selection of a highly-anticipated abstract which will detail data from the MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. Specifically, Ian looks to learn more about the potential prevention of progression of fibrosis. Jörn adds the note that this abstract will be the firs...2023-06-1713 minSurfing the MASH TsunamiS4-E27 - EASL Congress 2023 Preview: Great Talks to Anticipate!Surfing NASH serves yet another preview of a highly anticipated and upcoming EASL Congress in Vienna, this time focusing on a strong lineup of fascinating abstracts and engaging sessions. This episode is split into three digestible sections. First up, Louise Campbell speaks to Roger Green about anticipations around the program and which abstracts are eye-catching and why. Next, Ian Rowe and Jörn Schattenberg join Roger to address a similar set of questions from their unique perspectives. Finally, the podcast has partnered with HistoIndex to produce a topical extra-sode around AI and pathology with Arun Sanyal and David Kleiner. T...2023-06-151h 29Surfing the MASH TsunamiS4-E3.6 - Interview with Co-founder & CSO of HistoIndex, Dean Tai, on AI-Assisted HistologyIn an exclusive interview, Co-Founder and Chief Scientific Officer of HistoIndex, Dr. Dean Tai, joins Fatty Liver Researcher Prof. Dr. Jörn Schattenberg on Surfing the NASH Tsunami podcast with host, Roger Green. The trio discuss pertinent questions stemming from data derived from Phase 2 trial results of aldafermin and resmetirom whereby liver volume reduction was achieved in a considerably abbreviated period. HistoIndex was able to subsequently investigate fibrosis reduction in these studies by conducting AI-assisted histologic assessment to gather a deeper understanding of fibrosis dynamics on a continuous scale.Jörn introduces the corresponding poster held at NA...2023-01-1525 minSurfing the MASH TsunamiS4-E3.4 - NASH-TAG Review: Insights on the F3 Population and AI-Assistance for Improving Therapeutic EfficacyNASH-TAG 2023 proved to be a watershed moment for Fatty Liver disease as exciting drug development readouts, powerful academic work on non-invasive tests and the willingness to dive into the toughest questions aligned in Deer Valley, Utah. In this weekend’s conversation series, Surfing NASH reviews its diverse coverage of the conference by showcasing key excerpts across six recordings with various KOLs, patient advocates and stakeholders.This conversation with Naim Alkhouri, Amy Articolo and Jörn Schattenberg begins with Naim illustrating some of the high points of the meeting. First, he recaps the resmetirom data. He then highlights tha...2023-01-1518 minSurfing the MASH TsunamiS4-E2 - NASH-TAG 2023, Part 2: Friday and Saturday Takeaways and AI-Assisted Histologic AssessmentIn Part 2 of our real time coverage of the highly anticipated NASH-TAG 2023 conference, friends of the podcast Scott Friedman and Rachel Zayas join Louise Campbell, Jörn Schattenberg and Roger Green to review key takeaways from Friday and Saturday in Deer Valley. Following this session, Jörn, Louise and Roger review high points from the Saturday night “Potpourri” and “Regulatory Fireside Chat” sessions. The final feature of this episode is an enthralling and exclusive interview with HistoIndex Co-Founder and Chief Scientific Officer, Dean Tai, who shares captivating data from an AI-assisted histologic assessment of Phase 2 trials on aldafermin and resmetirom...2023-01-081h 35Surfing the MASH TsunamiS3-E14.5 - Improving Ballooned Hepatocyte Analysis Through Artificial IntelligenceThe episode and this conversation is sponsored by HistoIndex. This specific conversation focuses on ways and AI-assistive technologies and analyses can improve our abilities to assess efficacy in drugs that treat advanced fibrosis and cirrhosis.For this extrasode, HistoIndex Chief Scientific Officer Dean Tai joins Quentin Anstee, Mazen Noureddin, Joern Schattenberg and Roger Green to discuss how AI-based algorithms can support improved analysis of ballooned hepatocyte changes both in advanced fibrosis and cirrhosis patients.The rest of the conversation probes how this work will affect diagnosis and drug development, what other tests panelists can foresee...2022-03-1442 minSurfing the MASH TsunamiS3-E14.4 - Ballooned Hepatocyte Analysis and Reassessing Drug DevelopmentOne major discussion at NASH-TAG this year was about the inconsistency in ballooned hepatocyte identification and how this inconsistency inflates screen fail rates and possibly placebo response across studies. This conversation is part of a thorough exploration of this issue.This conversation starts with Roger Green wrapping up the earlier discussion of the relationship between holistic NASH assessment and ballooned hepatocyte scoring by saying it is not surprising that fibrosis is an element in ballooned cell scoring, given that pathologists start with a holistic assessment and work back from there.Jörn Schattenberg asks Quentin A...2022-03-1311 minSurfing the MASH TsunamiS3-E14.3 - Systematic Flaws in Semi-Quantitative Ballooned Hepatocyte AnalysisOne major discussion at NASH-TAG this year was about the inconsistency in ballooned hepatocyte identification and how this inconsistency inflates screen fail rates and possibly placebo response across studies. This conversation is part of a thorough exploration of this issue.This conversation starts with Roger Green asking Stephen Harrison how clinical trial analysis might change for the better pending implementation of what researchers learned in this study. Stephen suggests that the area in greatest need of improvement is efficacy analysis at the back end of clinical trials. Specifically Stephen notes that variability in placebo response rates is...2022-03-1313 minSurfing the MASH TsunamiS3-E14.2 - Can We Manage Statistical Error in Ballooned Hepatocyte Analysis Better?One major discussion at NASH-TAG this year was about the inconsistency in ballooned hepatocyte identification and how this inconsistency inflates screen fail rates and possibly placebo response across studies.This conversation is part of a thorough exploration of this issue. It starts with Mazen Noureddin raising two questions about the entire subject of ballooned hepatocyte scoring in NAS assessment: should we use it at all, and if we should, should we move immediately to AI as the key to analysis?Quentin provides nuanced answers to both questions. On the issue of ballooned hepatocytes, he notes...2022-03-1212 minSurfing the MASH TsunamiS3-E14.1 - How Ballooned Hepatocyte Analytics Weaken NASH Clinical TrialsOne major discussion at NASH-TAG this year was about the inconsistency in ballooned hepatocyte identification and how this inconsistency inflates screen fail rates and possibly placebo response across studies.This conversation explores that issue in detail. It begins with Quentin Anstee eloquently laying out the challenge that led to this study and the approach it took.The challenge: recent studies have produce Kappa values for coding NAS scores in the 0.55 - 0.60 range. These scores suggests a level of error-related noise that might swamp a signal that a drug actually works.The solution: nine of...2022-03-1214 minSurfing the MASH TsunamiS3-E14 - NAS Scores and the Challenge of Complex Ballooned HepatocytesOne major discussion at NASH-TAG this year was about the inconsistency in ballooned hepatocyte identification and how this inconsistency inflates screen fail rates and possibly placebo response across studies. This episode explores that issue in detail.The episode is sponsored by HistoIndex. At the back of the episode is a discussion of how artificial intelligence driven assistive technology can improve the consistency of ballooned hepatocyte scoring in advanced fibrosis and support development of robust outcomes for fibrosis studies.This conversation includes three of the paper's authors, including last author Quentin Anstee. The conversation starts with...2022-03-101h 34
Digital-Pathology-TodaySeason 2, Episode 16 - Gideon Ho, PhD - The World’s First Fully Automated, Quantitative, Stain-Free Imaging System.Imagine a world without staining… in the excitement of digital pathology we often forget that we're using with a legacy system of staining tissue pink and purple, which is time-consuming and tissue-destructive. There's got to be a better way.
Our guest is Dr. Gideon Ho, who co-founded HistoIndex to develop and commercialize the world’s first fully automated, quantitative, stain-free imaging system.
Under his direction as the CEO, the laser-based stain-free imaging system has been
successfully implemented in academic, clinical and commercial research centers in major universities, hospitals and research facilities around the world. Dr. Ho has multiple patents and jour...2022-01-2727 minSurfing the MASH TsunamiS2-E60.2 - Previewing NASH-TAG 2022 Sessions 4-6 - Focus On the Major Consortia and Artificial IntelligenceNASH-TAG 2022 takes place in Deer Valley Utah and on-line from January 7-8, 2022. Join Surfing NASH to learn about important updates from the three consortia (LITMUS, NIMBLE and the NIH Cirrhosis Network), "new news" in wet biomarkers and combination therapy and a stimulating session with PathAI and Histoindex covering artificial intelligence.Co-chair Stephen Harrison leads the panel through key sessions from NASH-TAG. This conversation starts with a review of Session 4, in which Quentin Anstee presents updates from the LITMUS consortium, Arun Sanyal presents updates from NIMBUS, and Vijay Shah provides information about the NIH Cirrhosis Network. From there...2021-12-1115 minSurfing the MASH TsunamiS2-E60 - Explore Major Upcoming Events and Issues for NAFLD and NASH At Our NASH-TAG 2022 PreviewNASH-TAG 2022 Co-chair Stephen Harrison and Steering Committee Member Jörn Schattenberg review the upcoming conference, focusing on major issues in NAFLD and NASH diagnosis, staging, treatment and monitoring.NASH-TAG 2022 faculty, format and schedule suggest that this conference will produce breakthroughs in knowledge and consensus about NAFLD therapy. This week, NASH-TAG 2022 Steering Committee member Jörn Schattenberg joins the Surfers to discuss key presentations and critical issues in the conference. NASH-TAG co-chair Stephen Harrison walks the panel and audience through the entire NASH-TAG agenda, with Jörn, Louise Campbell and Roger Green contributing questions and comments throughout the ses...2021-12-0949 min
Dialogues on AI Digital PathologySpecial Episode (PART 4) - Conversation with KOL Hepatologists and Pharma Thought Leaders in NASHWe’re very happy to bring you Part 4 that will wrap up the Special Episode podcast of Dialogues on AI Digital Pathology!
In this Part 4 podcast, our guests – KOL Hepatologists and Pharma Thought Leaders in NASH – continue their discussions in response to questions by Pharma companies and clinical investigators. Find out their views on how AI Digital Pathology (AI-DP) can effectively impact NASH drug development, preclinical studies and clinical practice with granular histopathological data.
Please click here to view the Key Takeaways for Part 4 or go to https://tinyurl.com/b4ttvb4s.
...2021-06-0749 min
Dialogues on AI Digital Pathology[Official Trailer] Special Episode (PART 4) - Conversation with KOL Hepatologists and Pharma Thought Leaders in NASHDialogues on AI Digital Pathology is releasing Part 4 of its Special Episode real soon!
Listen to this trailer for a snippet of Part 4 with our guests, KOL hepatologists and Pharma Thought Leaders in NASH, as they continue their discussions on AI Digital Pathology (AI-DP), and the application and future of AI-DP in clinical practice, liver research, and drug development.
Guests
Prof. Stephen Harrison, Medical Director, Pinnacle Clinical Research
Prof. Vlad Ratziu, Professor of Hepatology, Sorbonne University and Pitié-Salpêtrière Hospital
Dr. Judith Ertle, Sen...2021-06-0303 minDialogues on AI Digital PathologySpecial Episode (PART 3) - Conversation with KOL Hepatologists and Pharma Thought Leaders in NASHGuests
Prof. Stephen Harrison (Pinnacle Clinical Research)
Prof. Vlad Ratziu (Sorbonne University Pitié-Salpêtrière Hospital)
Dr. Judith Ertle (Boehringer Ingelheim)
Dr. Karin Conde-Knape (Novo Nordisk)
Ms. Kitty Yale (Akero Therapeutics)
Moderator
Dr. Nikolai Naoumov (Novartis)
Key Takeaways
1) The innovation and qualities that AI Digital Pathology (AI-DP) brings to drug development can be described as a disruptive technology as it expands the knowledge of NASH pathobiology, introduces standardization and reproducibility on a fully qua...2021-05-1757 min
Dialogues on AI Digital Pathology[Official Trailer] Special Episode (PART 3) - Conversation with KOL Hepatologists and Pharma Thought Leaders in NASHOur Special Episode conversation on AI Digital Pathology in NASH Drug Development continues (in Parts 3 and 4) with our guests, KOL hepatologists and Pharma Thought Leaders in NASH, as they respond to questions by Pharma companies and clinical investigators on how AI Digital Pathology (AI-DP) can augment clinical trial data and work alongside pathologists to detect granular information that could be pivotal for determining patient recruitment, staging and treatment responses. The full Part 3 podcast will be launched early next week, so click here to listen to the Trailer of Part 3!
A huge Thank You...2021-05-1403 minDialogues on AI Digital PathologySpecial Episode (PART 2) - Conversation with KOL Liver PathologistsOur guest KOL liver pathologists continue their conversation from Part 1 following the FDA Webcast, by responding to more questions by Pharma companies and clinical investigators on how AI Digital Pathology (AI-DP) can aid pathologists with precise assessment to better interpret the disease biology of NASH.
We’d like to thank our Guests and Moderator for their kind participation and professional views!
Prof. Pierre Bedossa
Professor of Pathology at the University of Paris; Consultant in Liver Pathology at LIVERPAT, Paris, France
Prof. Zachary Goodman
...2021-03-1740 min
Dialogues on AI Digital Pathology[Official Trailer] Special Episode (PART 2) - Conversation with KOL Liver PathologistsHere's the Official Trailer for Part 2 of our Special Episode of Dialogues on AI Digital Pathology, which is coming up in a week! Listen to these sound bites from our guest KOL liver pathologists, Professor Pierre Bedossa, Professor Zachary Goodman, and Professor David Kleiner as they speak to our Moderator, Dr Nikolai Naoumov about AI digital pathology as a complementary tool for pathologists in interpreting the disease biology of NASH. This is a continuation from Part 1, where the KOLs comment on the key takeaways from the recent FDA webcast on NASH Drug Development, and questions from the industry on...2021-03-1203 minDialogues on AI Digital PathologySpecial Episode (PART 1) - Conversation with KOL Liver PathologistsWe’re very excited to bring you a Two-Part Special Episode of Dialogues on AI Digital Pathology!
Listen to our guests, KOL liver pathologists as they discuss the recent FDA Webcast on NASH drug development and utilization of AI digital pathology as potential clinical trial endpoints.
Here’s Part 1, where the KOL liver pathologists will discuss key takeaways from the recent FDA Webcast on NASH Drug Development, and respond to questions sent in by Pharma companies and clinical investigators on potential clinical trial strategies using AI digital pathology following the Webcast.
2021-03-0957 min
Dialogues on AI Digital Pathology[Official Trailer] Season 2, Episode 1, Part 1 - Special Podcast with KOL Liver PathologistsWe're commencing Season 2 with a two-part Special Episode of Dialogues on AI Digital Pathology!
This episode brings together our guests, Key Opinion Leaders in liver pathology, who will be speaking about the key takeaways from the recent FDA webcast on NASH Drug Development, and responding to questions from the industry on designing clinical trial strategies with AI digital pathology. Here's a Trailer of this special episode's Part 1 with snippets from Professor Pierre Bedossa, Professor Zachary Goodman, and Professor David Kleiner as they speak to our Moderator, Dr Nikolai Naoumov.
Guests
...2021-03-0503 minDialogues on AI Digital PathologyEpisode 4 with Dr. Nikolai Naoumov [Full Podcast]In this episode*, we speak to Dr. Nikolai Naoumov, MD, PhD, FRCP, FRCPAth, FAASLD (Adviser for Clinical Research and Drug Development in Liver Diseases at Novartis, and physician-scientist and specialist in liver diseases). With his current focus on AI digital pathology in assessing liver biopsies, NASH combination therapies, HBV cure and liver fibrosis, Nikolai speaks to us on the changing landscape of drug development for NASH fuelled by advances in AI digital pathology.
*This episode concludes Season 1 of Dialogues on AI Digital Pathology, and we will be commencing our second podcast season in mid-2021. Meanwhile, the webinars...2020-12-0839 min
Dialogues on AI Digital Pathology[Official Trailer] Episode 4 with Dr Nikolai NaoumovIn the upcoming episode 4 of Dialogues on AI Digital Pathology, we speak to Dr. Nikolai Naoumov, MD, PhD, FRCP, FRCPAth, FAASLD (Adviser for Clinical Research and Drug Development in Liver Diseases at Novartis). Nikolai is a physician-scientist with a professional career combining academic research, clinical care and drug development – all focused on liver diseases. With his current work focusing on digital pathology with AI assessment of liver biopsies, NASH combination therapies, HBV cure and liver fibrosis, Nikolai shares his views about the advantages and impact of AI digital pathology in drug development efforts for NASH.2020-12-0200 minDialogues on AI Digital PathologyEpisode 3 with Dr. Suneil Hosmane [Full Podcast]Listen to our guest, Dr. Suneil Hosmane (Executive Vice President and Global Head of Diagnostics at GENFIT), as he speaks about the role of AI digital pathology, the latest NIS4 blood-based diagnostic test by Genfit and how AI digital pathology can work with non-invasive technologies (NITs) to enhance drug development efforts in NASH clinical trials today that could ultimately transform the NASH clinical care pathway.2020-11-0300 min
Dialogues on AI Digital Pathology[Official Trailer] Episode 3 with Dr Suneil HosmaneEpisode 3 of Dialogues on AI Digital Pathology is coming up soon! Here's a sound bite from our guest, Dr. Suneil Hosmane, Executive Vice President and Global Head of Diagnostics at GENFIT, who will share his views on how AI digital pathology can work with non-invasive technologies (NITs) to enhance drug development efforts and benefit patient outcomes. Watch out for our updates next week when Episode 3 goes Live! 2020-10-2800 minDialogues on AI Digital PathologyEpisode 2 with Dr. David Kleiner feat. Dr Dean Tai [Full Podcast]In Episode 2 of Dialogues on Digital Pathology, we speak to Dr. David Kleiner, Senior Research Physician and Chief of Post-mortem Section, Laboratory of Pathology, from the Center for Cancer Research at the National Cancer Institute.
Dr. Kleiner will be sharing his views on AI digital pathology and how it can work hand-in-hand with liver pathologists to empower NASH drug development and clinical practice. During the Q&A segment, Dr. Kleiner will be joined by supporting guest, Dr. Dean Tai, Chief Scientific Officer of HistoIndex, who will provide his insights on the role of machine learning...2020-10-1300 minDialogues on AI Digital Pathology[Official Trailer] Episode 2 with Dr David Kleiner feat. Dr Dean TaiWatch out for our upcoming episode next week with our guest, Dr David Kleiner, Senior Research Physician and Chief of Post-mortem Section, Laboratory of Pathology, from the Center for Cancer Research at the National Cancer Institute. Dr Kleiner shares his view on AI digital pathology and its abilities in working hand-in-hand with liver pathologists and empowering NASH drug development.
The full episode will be launched in a few days, and will include a Q&A segment with supporting guest, Dr Dean Tai, Chief Scientific Officer of HistoIndex. Enjoy the trailer!
Featured Music by...2020-10-0800 minDialogues on AI Digital PathologyEpisode 1 with Dr Stephen Harrison [Full Podcast]In our inaugural episode, we speak to Dr Stephen Harrison (Medical Director of Pinnacle Clinical Research) on the role AI digital pathology can play in current NASH drug development.2020-08-1754 min
Dialogues on AI Digital Pathology[Official Trailer] Episode 1 with Dr Stephen HarrisonWelcome to Dialogues on AI Digital Pathology, a podcast/webinar series where medical and industry experts will be sharing their views on the evolving trends of AI digital pathology and its role in finding effective treatments for Nonalcoholic Steatohepatitis (NASH). We look forward to bringing you more insights on AI digital pathology in every episode, so do stay tuned!
Featured Music by Kevin MacLeod
Cover Art Image by Matt Botsford on Unsplash2020-08-1201 min